This trial is testing the combination of leflunomide, pomalidomide, and dexamethasone to treat patients with multiple myeloma that has returned or is resistant to treatment.
- Multiple Myeloma
1 Primary · 6 Secondary · Reporting Duration: Up to 1 year
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (leflunomide, pomalidomide, dexamethasone)
1 of 1
29 Total Participants · 1 Treatment Group
Primary Treatment: Leflunomide · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What conditions is leflunomide typically employed to address?
"Leflunomide can be prescribed to ease ophthalmic and sympathetic conditions, including branch retinal vein occlusion, macular edema, and assorted eye-related maladies." - Anonymous Online Contributor
Are there still vacancies for participants in this experiment?
"Affirmative. Clinicaltrials.gov provides proof that this research is currently in the process of recruiting participants, with the initial posting having been made on November 27th 2020 and last updated on January 10th 2022. In total 29 people are needed to be enrolled at one medical site." - Anonymous Online Contributor
Have any other studies explored the efficacy of utilizing Leflunomide?
"To date, 583 medical trials are currently investigating the uses of leflunomide with 146 studies in its advanced phase 3. Most clinical research is conducted in Mishawaka, Indiana; nevertheless, there are 18799 locations across the globe conducting experiments involving this drug." - Anonymous Online Contributor
Does the Food and Drug Administration condone leflunomide?
"Taking into consideration that Leflunomide is in Phase 2 of its clinical trials, our team at Power have surmised a safety rating of 2 for the drug due to existing data on its security but no evidence yet supporting efficacy." - Anonymous Online Contributor
How many participants are engaged with this research endeavor?
"Confirmed. Clinicaltrials.gov displays that this medical trial, which was first announced on November 27th 2020, is still actively recruiting participants from one location with a target of 29 enrollees." - Anonymous Online Contributor